

This case encapsulates the volatile nature of hematologic disorders, illustrating how diseases like MDS and non-secretory MM can morph and evolve. It emphasizes the importance of adaptive management, especially in elderly patients, where rigid treatment paradigms may fall short. The use of lenalidomide throughout the patient's journey reflects its dual utility in both plasma cell and myeloid disorders, while also sparking questions about whether prolonged exposure could influence secondary disease development. **Conclusion:** The patient's journey through MDS, MM, and back again underscores the critical need for dynamic reassessment, vigilance, and personalized care. This case exemplifies the blurred boundaries between plasma cell dyscrasias and myeloid neoplasms, raising thought-provoking questions about disease progression and therapeutic strategies. In navigating these complexities, clinicians are reminded of the importance of flexible, patient-centered approaches in managing intricate hematological disorders.

Keywords: Myelodysplastic Syndrome, Non-Secretory Multiple Myeloma, Disease Evolution, Adaptive Treatment, Elderly Patient Care.

<https://doi.org/10.1016/j.htct.2024.11.022>

OP 22

BRAIN-INVOLVED MULTIPLE MYELOMA: STABILITY ACHIEVED WITH BENDAMUSTINE-POMALIDOMIDE, RADIOTHERAPY AND DARATUMUMAB-BASED THERAPY

Bengisu Ece Duman ^{1,*}, Büşra Akdoğan ¹, Birol Güvenç ²

¹ Cukurova University Medical Faculty Hospital, Department of Internal Medicine

² Cukurova University Medical Faculty Hospital, Department of Internal Medicine, Division of Hematology

Objective: Multiple myeloma is a plasma cell malignancy that mainly affects the bones and skeletal system. The involvement of the brain as a site is very rare; it usually takes place via calvarial lesions with intracranial extension and is considered resistant to treatment. This report presents the case of a patient presenting with refractory MM and discusses in detail the efficiency of bendamustine-pomalidomide therapy and daratumumab-based maintenance after ASCT. **Case Report:** A 62-year-old female was diagnosed with kappa-positive MM in 2015, when plasma cell infiltration in the bone marrow was 20%. The patient underwent chemotherapy followed by ASCT in 2016. This patient attained remission after the transplant. Three years later, she presented with brain involvement, and MRI confirmed lesions of the parietal calvarium along with soft tissue expansion into the brain. The patient received radiotherapy to the affected area of the brain and initiated bendamustine-pomalidomide therapy; indeed, remarkable improvements were made in lesions of the brain and skeleton. Following that response, daratumumab, lenalidomide,

and dexamethasone maintenance therapy was initiated to ensure ongoing disease control. Currently, the patient is clinically stable, with no evidence of further progression on follow-up imaging. **Discussion:** This case underlines the rarity of brain involvement in MM, as well as the role of ASCT as part of first-line treatment. The late appearance of extramedullary brain involvement three years post-transplantation truly epitomizes the whim of MM. Bendamustine-pomalidomide therapy was effective for refractory disease management, whereas daratumumab-based maintenance has helped maintain stability.

Keywords: Multiple Myeloma, Brain Involvement, Extramedullary Disease, Bendamustine, Autologous Transplantation.

<https://doi.org/10.1016/j.htct.2024.11.023>

OP 23

SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY

Naciye Nur Tozluklu ^{1,*}, Birol Guvenç ²

¹ Cukurova University Medical Faculty Hospital, Department of Internal Medicine,

² Cukurova University Medical Faculty Hospital, Department of Internal Medicine, Division of Hematology

Chronic Lymphocytic Leukemia (CLL) typically affects older individuals and is frequently associated with genetic mutations that help predict its progression. However, this report presents a rare case of aggressive CLL in a young woman with no unfavorable genetic markers, who achieved lasting remission following the use of dual targeted therapy, after standard treatments repeatedly failed. A 40-year-old woman was diagnosed with CLL during a routine blood examination. Despite lacking any high-risk genetic indicators, her disease advanced swiftly over the next ten years. Initial treatment with CVP (cyclophosphamide, vincristine, prednisone) provided only a brief partial remission. A subsequent course of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) also led to relapse within a few months. Ibrutinib was introduced as a single-agent treatment but failed to control the disease. The patient's condition continued to deteriorate, with recurring lymph node enlargement and rising lymphocyte counts. Three years ago, venetoclax was added to her treatment alongside ibrutinib. This combination therapy produced an extraordinary result—complete remission was achieved, blood counts normalized, lymphadenopathy disappeared, and bone marrow tests showed no trace of residual disease.

Keywords: Chronic Lymphocytic Leukemia, Early-Onset CLL, Resistant CLL, Venetoclax, Ibrutinib.

<https://doi.org/10.1016/j.htct.2024.11.024>